Quest Diagnostics (DGX, Financial) has received a price target increase from Truist analyst David MacDonald, moving up to $190 from the previous $182. This update comes in the wake of the company's robust performance in the first quarter. Despite revenue meeting expectations, Quest Diagnostics surpassed predictions with its adjusted earnings per share and adjusted operating income.
The firm also reaffirmed its guidance for the fiscal year 2025, reinforcing confidence in its financial trajectory. MacDonald maintains a Hold rating on the shares, citing several positive developments. Among these is the recent court ruling favoring laboratory-developed tests (LDT), which is seen as a beneficial development for Quest. Additionally, positive remarks regarding tariff impacts and anticipated gains from ongoing artificial intelligence and automation initiatives suggest improved efficiency and cost savings moving forward.
These factors combined paint a favorable outlook for Quest Diagnostics, with analysts anticipating steady progress due to strategic enhancements and supportive market conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Quest Diagnostics Inc (DGX, Financial) is $183.22 with a high estimate of $198.00 and a low estimate of $160.00. The average target implies an upside of 6.01% from the current price of $172.84. More detailed estimate data can be found on the Quest Diagnostics Inc (DGX) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Quest Diagnostics Inc's (DGX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Quest Diagnostics Inc (DGX, Financial) in one year is $156.78, suggesting a downside of 9.29% from the current price of $172.84. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Quest Diagnostics Inc (DGX) Summary page.
